A condition that affects the blood, known as idiopathic thrombocytopenic purpura (ITP), may be associated the Oxford-AstraZeneca vaccine in rare cases, research suggests.
A clinical study getting underway in Rotorua and Christchurch will provide valuable information on how our unique population responds to the Pfizer-BioNTech COVID-19 vaccine. The study, ‘Ka Mātau, Ka Ora' (from knowledge comes wellbeing), is being .
Idiopathic thrombocytopenic purpura (ITP), a condition that affects the blood by low platelet count, may be associated the Oxford-AstraZeneca COVID vaccine in rare cases.